O-Methyldiphenhydramine en es it fr

O-Methyldiphenhydramine Brand names, O-Methyldiphenhydramine Analogs

O-Methyldiphenhydramine Brand Names Mixture

  • No information avaliable

O-Methyldiphenhydramine Chemical_Formula


O-Methyldiphenhydramine RX_link


O-Methyldiphenhydramine fda sheet

O-Methyldiphenhydramine FDA

O-Methyldiphenhydramine msds (material safety sheet)

O-Methyldiphenhydramine MSDS

O-Methyldiphenhydramine Synthesis Reference

No information avaliable

O-Methyldiphenhydramine Molecular Weight

269.381 g/mol

O-Methyldiphenhydramine Melting Point

156-157 oC

O-Methyldiphenhydramine H2O Solubility

Sparingly soluble in water

O-Methyldiphenhydramine State


O-Methyldiphenhydramine LogP


O-Methyldiphenhydramine Dosage Forms

Tablet (extended-release)

O-Methyldiphenhydramine Indication

Indicated for the treatment of Parkinson's disease.

O-Methyldiphenhydramine Pharmacology

Orphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anaesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favourable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. The effect is somewhat less on bradykinesia.

O-Methyldiphenhydramine Absorption

Orphenadrine is almost completely absorbed in the gastrointestinal tract.

O-Methyldiphenhydramine side effects and Toxicity

Oral, mouse LD50 = 100 mg/kg; oral, rat LD50 = 255 mg/kg

O-Methyldiphenhydramine Patient Information

No information avaliable

O-Methyldiphenhydramine Organisms Affected

Humans and other mammals